News

It will be marketed and distributed by Hetero Healthcare Limited, a group company of Hetero. The launch of biosimilar Rituximab will provide a much needed access to patients

Arch management anticipates that similar patents will be issued, in due course, in various major national markets that are members of the Patent Cooperation Treaty. This U.S. patent

These targeted therapies are being developed at a time when cardiovascular, neurodegenerative and metabolic lifestyle diseases are approaching epidemic stages, and viral and bacterial infectious disease conditions are

DMD is a recessive X-linked form of muscular dystrophy, which results in muscle degeneration, difficulty walking, breathing and ultimately death. Diagnosis typically occurs between the ages of 2

The first license agreement is with the Indiana University Research and Technology Corporation (IURTC) and the second is with the IURTC and the University of Alabama at Birmingham

Viberzi, an orally active compound indicated to treat IBS-D in men and women, has mixed opioid receptor activity and is a mu receptor agonist, a delta receptor antagonist

FAP affects an estimated one in 10,000 people across the world and is associated with a near 100% risk of colon cancer if untreated. Additionally, the company announced

Aerie is focused on the discovery, development and commercialization of first-in-class therapies for patients with glaucoma and other diseases of the eye. GrayBug develops microparticle controlled release drug

As part of the deal, a Phase I/II trial will be conducted to evaluate the safety and efficacy of MedImmune’s durvalumab (MEDI4736) in combination with Mirati’s mocetinostat in